Older adults

Follow-up results from the WISDM trial show that extended use of continuous glucose monitoring leads to reduced hypoglycemia without increasing hyperglycemia risk in older people with type 1 diabetes.

Findings from the ORACL trial suggest that closed-loop insulin delivery results in better glycemic control than sensor-augmented pump therapy among older adults with longstanding type 1 diabetes.

Among older people with type 2 diabetes, use of SGLT2 inhibitors is associated with improved glycemic control and a favorable safety profile, suggests research reported at the virtual 57th EASD Annual Meeting.

Keeping glycated hemoglobin levels within individualized target ranges over time is associated with reduced risk for mortality and cardiovascular disease in older adults with diabetes, suggest results from an observational study.

Older people with type 2 diabetes are more likely to receive inappropriately intensive glucose-lowering treatment if they live in high- versus middle income countries, show data from the global DISCOVER study.

Older individuals with type 2 diabetes and low glycated hemoglobin receiving treatment with a sulfonylurea or insulin have an increased risk for severe hypoglycemia, but there is no clear indication of an increased mortality risk, suggest UK study results.

Researchers find that older adults with diabetes are frequently treated to an intensive glycemic target, putting them at risk for poor outcomes, particularly when high-risk agents are used.

Older people with and without diabetes experience similar short-term improvements in exercise capacity following cardiac rehabilitation, but those with diabetes fare worse after 1 year, EU-CaRE study results suggest.

The effect of glycemic control on all‐cause mortality risk depends on diabetes duration in people aged 65 years and older with type 2 diabetes, study findings indicate.

The addition of linagliptin to stable insulin treatment improves glycemic control without increasing the risk for clinically important hypoglycemia among older individuals with type 2 diabetes, randomized trial findings suggest.

Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity.

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

Research shows an increased mortality risk associated with the use of intensive antidiabetes treatments in older patients with type 2 diabetes.

Zhu B et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1181-4

Saetung S et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1166-3

McCarthy MM, Grey M. Diabetes Care 2018. doi: 10.2337/dc17-2597

Forbes et al. The Lancet Diabetes & Endocrinology 2018. doi: 10.1016/S2213-8587(18)30048-2

The excess mortality risk associated with high or very low glycated hemoglobin values is modified by glycemic variability in diabetes patients aged 70 years or more, shows an analysis of The Health Improvement Network database.

Results of a longitudinal study show that diabetes and poor glycemic control are associated with long-term cognitive decline among older people in the UK.

Glycated hemoglobin levels deteriorate only slowly in most type 2 diabetes patients who are newly diagnosed when aged 70 years or older, say researchers.